Six hedge funds have recently purchased shares of this biotech.
Cassava Sciences, Inc. (SAVA)
From Cotton’s Technically Speaking
Cassava Sciences, Inc. is a clinical stage biotechnology company that develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125 which has completed a Phase 2b clinical trial for Alzheimer’s, with very significant results. It it actually appeared to improve the symptoms of the disease, not just halt or slow the progress of the disease.
The company just raised $75 Million in November to fund their third phase trials, which, if successful, could result in a billion dollar Blockbuster Drug.
Cassava also has a blood based diagnostic product to detect Alzheimer’s disease in the works.
We bought the stock on 12/17/20 at $8.42 along with the SA VA January 152021 7.5 Calls @ $1.46.
Joseph Cotton, Cotton’s Technically Speaking, cottonstocks.net, 727-289-4436, December 18, 2020